What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Acute coronary syndrome (n=584249). Intervention: Bivalirudin vs. Heparin. Primary outcome: In-hospital all-cause mortality (RR 0.86, 95% CI 0.84-0.88, p=<0.001).

What does this research mean for the field?

In patients with acute coronary syndrome undergoing percutaneous coronary intervention, bivalirudin significantly reduces in-hospital and 30-day all-cause mortality and major bleeding compared with heparin, without significant differences in ischemic outcomes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate and compare the clinical safety and efficacy of bivalirudin versus heparin in patients diagnosed with acute coronary syndrome undergoing percutaneous coronary intervention.

September 28, 2026MedicineOpen Access

Comparison of bivalirudin versus heparin in percutaneous coronary intervention for patients with acute coronary syndrome

Q: What are the key findings of this study?

Bivalirudin significantly reduced in-hospital all-cause mortality (RR 0.86) and major bleeding (RR 0.74) compared to heparin in patients with acute coronary syndrome undergoing PCI.

Q: What does this research mean for the field?

In patients with acute coronary syndrome undergoing percutaneous coronary intervention, bivalirudin significantly reduces in-hospital and 30-day all-cause mortality and major bleeding compared with heparin, without significant differences in ischemic outcomes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To evaluate and compare the clinical safety and efficacy of bivalirudin versus heparin in patients diagnosed with acute coronary syndrome undergoing percutaneous coronary intervention.

View Full Paper

Ask AI

Bookmark

Key result

Bivalirudin cuts in-hospital mortality ~14% vs. heparin in ACS patients undergoing PCI.

RR 0.86
95% CI 0.84-0.88
P<0.001
n=584,249

Why the study?

The comparative safety and efficacy of bivalirudin versus heparin in patients with ACS undergoing PCI remain to be clarified through comprehensive analysis.

Does bivalirudin reduce mortality and bleeding compared to heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention?

Population

584,249 patients with ACS undergoing PCI from 11 RCTs and 17 cohort studies

Comparison

Bivalirudin versus heparin

Design

Meta-analysis of RCTs and cohort studies

Follow-up

In-hospital and 30-day

Authors

CYChen Yang ZNZhen NingNanchang Institute of Technology WLWeiming LiangGuangxi University of Science and Technology

Discussion

Member takes

Implication

Supports bivalirudin over heparin in ACS PCI to lower mortality and bleeding; extends prior evidence with large mixed RCT-cohort meta-analysis.

Key Points

To evaluate and compare the clinical safety and efficacy of bivalirudin versus heparin in patients diagnosed with acute coronary syndrome undergoing percutaneous coronary intervention.
Systematically searched PubMed, Embase, Web of Science, and the Cochrane Library for randomized controlled trials and cohort studies.
Identified and analyzed 28 studies comprising 11 RCTs and 17 cohort studies encompassing 584,249 patients.
Evaluated primary and secondary endpoints including all-cause mortality, cardiovascular mortality, major bleeding, MACEs, net adverse clinical events, myocardial infarction, stent thrombosis, and stroke.
For in-hospital outcomes, bivalirudin significantly reduced all-cause mortality (RR = 0.86, 95% CI: 0.84-0.88, P < .001, I2 = 0%) and major bleeding (RR = 0.74, 95% CI: 0.62-0.88, P < .001, I2 = 51%) compared with heparin, without differences in MACEs (RR = 1.23, 95% CI: 0.89–1.68, P = .21, I2 = 0%).
For 30-day outcomes, bivalirudin significantly decreased all-cause mortality (RR = 0.85, 95% CI: 0.76-0.95, P = .006, I2 = 24%), cardiovascular mortality (RR = 0.81, 95% CI: 0.70-0.94, P = .004, I2 = 1%), major bleeding (RR = 0.59, 95% CI: 0.49-0.72, P < .001, I2 = 67%), and net adverse clinical events (RR = 0.79, 95% CI: 0.70-0.89, P < .001, I2 = 55%).
No significant differences occurred between groups for ischemic outcomes, including myocardial infarction, stent thrombosis, and stroke during hospitalization or at 30-day follow-up.

Study Design

Type

Meta-Analysis (n=584,249)

Structured PICO

Does bivalirudin reduce mortality and bleeding compared to heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention?

Population

584,249 patients with acute coronary syndrome undergoing percutaneous coronary intervention from 11 randomized controlled trials and 17 cohort studies, followed for up to 30 days.

Intervention

Bivalirudin

Comparator

Heparin

Outcome

All-cause mortality, cardiovascular mortality, major bleeding, major adverse cardiovascular events (MACEs), net adverse clinical events (NACE), myocardial infarction (MI), stent thrombosis (ST), and stroke at in-hospital and 30-day follow-uphard clinical

Main Result

Relative Risk: 0.86 (95% CI 0.84–0.88)

p-value: p=<0.001

In patients with ACS undergoing PCI, bivalirudin is associated with reduced in-hospital and 30-day all-cause mortality and major bleeding compared to heparin, without significant differences in ischemic outcomes.

Limitations

Majority of included studies were cohort studies, with a limited number of RCTs
Scarcity of long-term follow-up data beyond 30 days
Differences in baseline characteristics between studies may introduce selection bias
Significant statistical heterogeneity for key outcomes like major bleeding and NACE
Geographical homogeneity limits generalizability to low-income countries

Cite This Study

Yang et al. (2026) conducted a meta-analysis in Acute coronary syndrome (n=584,249). Bivalirudin vs. Heparin was evaluated on In-hospital all-cause mortality (RR 0.86, 95% CI 0.84-0.88, p=<0.001). Bivalirudin significantly reduced in-hospital all-cause mortality (RR 0.86) and major bleeding (RR 0.74) compared to heparin in patients with acute coronary syndrome undergoing PCI.

synapsesocial.com/papers/6ab9b54a7822ec8fc3d8fce8 https://doi.org/10.1097/md.0000000000050046

Topics

Percutaneous coronary intervention Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Implication

Supports bivalirudin over heparin in ACS PCI to lower mortality and bleeding; extends prior evidence with large mixed RCT-cohort meta-analysis.

Comparison of bivalirudin versus heparin in percutaneous coronary intervention for patients with acute coronary syndrome

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Topics

Comparison of bivalirudin versus heparin in percutaneous coronary intervention for patients with acute coronary syndrome

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Topics

Also Consider